https://orcid.org/0000-0002-7312-3664
References
- Hrabovský Š, Folber F, Doubek M. Therapy of relapsed/refractory acute lymphoblastic leukemia today and tomorrow. Klin Onkol. 2019;32:90–96.
- Garas A, McLean LA, De Luca CR, et al. Health-related quality of life in paediatric patients up to five years post-treatment completion for acute lymphoblastic leukaemia: a systematic review. Support Care Cancer. 2019;27:4341–4351.
- Winestone LE, Aplenc R. Disparities in survival and health outcomes in childhood leukemia. Curr Hematol Malig Rep. 2019;14:179–186.
- Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60:2606–2621.
- Salim KY, Maleki Vareki S, Danter WR, et al. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget. 2016;7:41363–41379.
- Lindemann A, Patel AA, Silver NL, et al. COTI-2, A novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. Clin Cancer Res. 2019;25:5650–5662.
- Maleki Vareki S, Salim KY, Danter WR, et al. Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS One. 2018;13:e0191766.
- Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269.
- Bueno MJ, Pérez de Castro I, Gómez de Cedrón M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13:496–506.
- Chim CS, Wong KY, Leung CY, et al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med. 2011;15:2760–2767.
- Kummar S, Gutierrez M, Doroshow JH, et al. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol. 2006;62:15–26.
- Zhang J, Zhou Y, Wu YJ, et al. Hyper-methylated miR-203 dysregulates ABL1 and contributes to the nickel-induced tumorigenesis. Toxicol Lett. 2013;223:42–51.
- Gasque Schoof CR, Izzotti A, Jasiulionis MG, et al. The roles of miR-26, miR-29, and miR-203 in the silencing of the epigenetic machinery during melanocyte transformation. Biomed Res Int. 2015;2015:634749.
- Chen W, Xu XK, Li JL, et al. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget. 2017;8:22783–22799.
- Chen M, Zhou L, Liao Z, et al. Sevoflurane inhibited osteosarcoma cell proliferation and invasion via targeting miR-203/WNT2B/Wnt/β-Catenin Axis. Cancer Manag Res. 2019;11:9505–9515.
- You HY, Xie XM, Zhang WJ, et al. Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation ofmiR-203. In Vitro Cell Dev Biol Anim. 2016;52:857–863.
- Hamano R, Miyata H, Yamasaki M, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011;17:3029–3038.
- Bian K, Fan J, Zhang X, et al. MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett. 2012;586:804–809.
- Zhang F, Yang Z, Cao M, et al. MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer. Cancer Lett. 2014;342:121–129.
- Li J, Chen Y, Zhao J, et al. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett. 2011;304:52–59.
- Wu SQ, Niu WY, Li YP, et al. miR-203 inhibits cell growth and regulates G1/S transition by targeting Bmi-1 in myelomacells. Mol Med Rep. 2016;14:4795–4801.